Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2025
|
| Online Access: | https://doi.org/10.5281/zenodo.17140810 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- <p><span>Orthodontic pain remains one of the most common and distressing experiences reported by patients undergoing fixed or removable orthodontic treatment. It is primarily associated with tissue compression, ischemia, periodontal ligament inflammation, and prostaglandin-mediated responses to tooth movement. Over the years, numerous pain management strategies have been employed, with systemic pharmaceutical agents such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and, less frequently, opioids being the mainstay of therapy. However, systemic administration poses risks of gastrointestinal irritation, renal impairment, drug–drug interactions, and reduced patient compliance. Novel localized drug delivery systems, including mucoadhesive wafers, have emerged as promising alternatives by providing targeted, sustained release of analgesics directly at the site of pain, thereby minimizing systemic side effects. This chapter examines the comparative effectiveness of wafers and conventional pharmaceuticals in orthodontic pain management, exploring their mechanisms of action, clinical outcomes, safety, and patient compliance. The integration of such advanced systems represents a step forward in personalizing orthodontic care and improving patient quality of life.</span></p>